| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Avosentan May Slow Progression Of Diabetic Kidney Disease WASHINGTON, DC -- February 12, 2009 -- Avosentan significantly lowers urinary protein excretion in patients with diabetic kidney disease, according to a study published early online and appearing in the March print issue of the Journal of the American Society Nephrology. The study's results suggest that avosentan may slow the progression of diabetic kidney disease and help prevent end stage disease. René R. Wenzel, MD, Paracelsus University, Salzburg, Austria, and colleagues investigated the potential of avosentan for reducing proteinuria in 286 patients with diabetic kidney disease. Patients were randomised to receive a placebo or 4 different doses of avosentan (5mg, 10mg, 25mg, 50mg) for 12 weeks in addition to standard therapy. The results showed that there was a marked and significant reduction of albuminuria even with lower doses of avosentan. Compared with values measured at the start of the study, all avosentan doses decreased patients' mean relative urinary albumin excretion rates (-16.3% to -29.9%) while the placebo did not (+35.5%). Because there seemed to be no additional beneficial effect with doses of avosentan above 25 mg, the optimal dose in terms of risk-benefit-ratio is likely to be 10 mg and below. According to the authors, the study indicates that avosentan given in addition to standard treatments could have a protective effect on the kidneys. They noted that a larger clinical trial is needed to confirm the study's findings and to determine whether avosentan's effects result in long-term benefits.
SOURCE: American Society of Nephrology
|